サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1753208

腸チフス・ワクチンの世界市場

Typhoid Fever Vaccines

出版日
ページ情報
英文 372 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.80円
腸チフス・ワクチンの世界市場
出版日: 2025年06月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 372 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

腸チフス・ワクチンの世界市場は2030年までに10億米ドルに達する見込み

2024年に4億3,060万米ドルと推定される腸チフス・ワクチンの世界市場は、分析期間2024-2030年にCAGR 15.7%で成長し、2030年には10億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである弱毒生ワクチンは、CAGR 16.9%を記録し、分析期間終了時には5億1,000万米ドルに達すると予測されます。Capsular Polysaccharide Vaccine（莢膜多糖体ワクチン）分野の成長率は、分析期間中CAGR 16.4%と推定されます。

米国市場は1億1,730万米ドルと推定、中国はCAGR21.0％で成長予測

米国の腸チフス・ワクチン市場は、2024年に1億1,730万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに2億2,660万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは21.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ11.4%と14.1%と予測されています。欧州では、ドイツがCAGR約12.5%で成長すると予測されています。

世界の「腸チフス・ワクチン」市場- 主要動向と促進要因のまとめ

腸チフスに対する世界の闘いはなぜかつてない勢いを増しているのか？

過去10年間、腸チフスとの闘いは、特に世界保健当局からの新たな注目と新規腸チフス・ワクチンの開発により、大きな変貌を遂げてきました。特に中低所得国（LMICs）における腸チフスの負担の増大は、予防ヘルスケア対策への大きな投資を引き起こしました。世界保健機関（WHO）によると、腸チフスは世界で毎年1,100万人から2,100万人が罹患し、約12万8,000人から16万1,000人が死亡しています。Typbar-TCV（腸チフス混合ワクチン）のようなワクチンは、免疫力が長期間持続し、若年層にも適用可能で、副作用のリスクが低いことから、重要な介入策として浮上してきました。さらに、パキスタンやジンバブエのような国々では、集団予防接種キャンペーンが展開され、有効性と費用対効果の両方が実証されています。高負担地域では水と衛生の改善だけでは不十分であるため、各国政府はワクチン・プログラムを国の予防接種スケジュールに組み込んでいます。さらに、ワクチン同盟であるGaviのような組織からの支援の拡大は、これらのワクチンの資金調達と配布を合理化し、最も必要としている地域での普及を加速させています。

イノベーションは、どのように腸チフス・ワクチンの有効性とリーチを形成しているのか？

腸チフスワクチンが従来の弱毒生ワクチンや不活化ワクチンから結合型ワクチンへと進化したことで、接種率、耐久性、年齢に応じた投与という点で極めて重要な進歩を遂げました。Ty21aやVi多糖体のような従来のワクチンには、年齢制限（通常2歳未満では無効）や免疫期間の短縮という点で限界がありました。しかし、新世代の腸チフス混合ワクチン（TCVs）は、6ヶ月の小児に投与でき、最長5年以上の予防効果があります。この開発は、流行地域における小児の予防接種戦略にとって重要な意味を持っています。さらに、腸チフス予防とパラチフスや侵襲性非腸チフス性サルモネラ菌（iNTS）などの他の腸疾患予防を組み合わせた多病原性結合型ワクチンの臨床試験が世界的に進められています。抗菌薬耐性（AMR）がサルモネラ・チフス株で増加し続け、従来の抗生物質療法が効きにくくなっているため、こうした技術革新は特に重要です。その結果、腸チフス制圧のための最も持続可能なアプローチとして、予防的免疫化が支持されつつあります。さらに、バイオテクノロジー企業は、遠隔地や資源不足の環境における課題であるコールドチェーン依存を軽減するため、耐熱性製剤に投資しています。

戦略的政策と国際協力はアクセシビリティ・ギャップを埋められるか？

世界のヘルスケア・エコシステムの相互接続が進むにつれ、政策的枠組みや国境を越えたパートナーシップの役割は、腸チフス・ワクチンの普及に不可欠なものとなっています。WHOによるTCVの事前認定は、国連機関による調達の門戸を開き、普及を促進しています。一方、Gaviによる対象国への資金援助により、特にサハラ以南のアフリカと南アジアでは、ワクチンが安価で入手しやすくなっています。こうした支援は、国内の政策改革によって補完されており、保健省は腸チフスワクチンを定期予防接種のスケジュールに組み込んでいます。さらに、NGO、保健省、国際的なドナーによる共同の取り組みは、監視システムの強化、地域社会の意識向上、シームレスな流通を確保するためのコールドチェーン基盤の強化に重点を置いています。腸チフス対策連合（Coalition against Typhoid）のような世界のイニシアティブもまた、アドボカシーを強化し、集団発生とワクチンの影響を監視するためのデータ主導のアプローチを促進しています。さらに、COVID-19の大流行は、予防接種システムを強化することの緊急性を浮き彫りにし、各国政府は予防ワクチン接種の役割を、より広範な健康回復のためのツールとして認識するようになっています。このような視点の転換により、新たな資金調達ルートが開拓され、これまで十分な支援が得られなかった地域での規制当局の承認が加速しています。

世界中で腸チフスワクチンの需要が急増しているのはなぜか？

腸チフス・ワクチン市場の成長の原動力は、公衆衛生の優先順位を変え、予防接種率を世界的に向上させているいくつかの要因です。第一に、多剤耐性（MDR）および広範囲薬剤耐性（XDR）腸チフス株の増加により、治療の選択肢が大幅に制限され、ワクチンが主要な防御ラインとして位置づけられています。第二に、多くのLMICsでは、水と衛生のインフラが改善されないまま都市化が著しく進んだため、高い感染率が維持され、予防対策への需要が高まっています。第三に、特にアジアとアフリカでは、腸疾患対策への政治的コミットメントが高まり、包括的な予防接種キャンペーンとヘルスケア予算の増額につながりました。さらに、診断サーベイランスの向上により、ホットスポットの特定が容易になったため、的を絞ったワクチン接種が可能になりました。技術的な面では、小児に適合し、有効性を拡大した1回接種のTCVの開発により、予防接種のロジスティクスが簡素化され、対象年齢が拡大しました。さらに、ヘルスリテラシーの向上と地域社会のワクチンへの取り組みにより、一般市民の受容性が向上し、ワクチン接種へのためらいが減少しています。最後に、世界的・地域的なワクチンメーカーの存在感の高まりは、サプライチェーンの信頼性を高め、技術革新と価格低下を促す競合環境を醸成しています。

セグメント

タイプ（弱毒生ワクチン,莢膜多糖体ワクチン,混合ワクチン,その他のタイプ）;投与経路（経口,注射）;エンドユーザー（病院&クリニック,専門医療機関,その他のエンドユーザー）

調査対象企業の例（注目の39社）

  • Bavarian Nordic A/S
  • Bharat Biotech International Ltd.
  • Biological E. Limited
  • Bio-Med Pvt. Ltd.
  • Cadila Healthcare Ltd.（Zydus Lifesciences）
  • Chiron Behring Vaccines Pvt. Ltd.
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • Haffkine Bio-Pharmaceutical Corp. Ltd.
  • Incepta Vaccine Ltd.
  • Indian Immunologicals Ltd.
  • Merck & Co., Inc.
  • Panacea Biotec Ltd.
  • PaxVax, Inc.
  • Pfizer Inc.
  • Prokarium Ltd.
  • Sanofi Pasteur
  • Serum Institute of India Pvt. Ltd.
  • Shanta Biotechnics Ltd.
  • SK bioscience Co., Ltd.

AI統合

私たちは、検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP35934

Global Typhoid Fever Vaccines Market to Reach US$1.0 Billion by 2030

The global market for Typhoid Fever Vaccines estimated at US$430.6 Million in the year 2024, is expected to reach US$1.0 Billion by 2030, growing at a CAGR of 15.7% over the analysis period 2024-2030. Live Attenuated Vaccine, one of the segments analyzed in the report, is expected to record a 16.9% CAGR and reach US$510.0 Million by the end of the analysis period. Growth in the Capsular Polysaccharide Vaccine segment is estimated at 16.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$117.3 Million While China is Forecast to Grow at 21.0% CAGR

The Typhoid Fever Vaccines market in the U.S. is estimated at US$117.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$226.6 Million by the year 2030 trailing a CAGR of 21.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.4% and 14.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.5% CAGR.

Global "Typhoid Fever Vaccines" Market - Key Trends & Drivers Summarized

Why Is The Global Fight Against Typhoid Gaining Unprecedented Momentum?

Over the past decade, the fight against typhoid fever has undergone a major transformation, especially due to renewed attention from global health authorities and the development of novel typhoid fever vaccines. The increasing burden of typhoid, particularly in low- and middle-income countries (LMICs), has triggered significant investments in preventive healthcare measures. According to the World Health Organization (WHO), typhoid fever affects between 11-21 million people globally each year, with approximately 128,000 to 161,000 deaths. Vaccines such as Typbar-TCV (Typhoid Conjugate Vaccine) have emerged as critical interventions due to their long-lasting immunity, applicability to younger age groups, and lower risk of adverse effects. What’s more, countries like Pakistan and Zimbabwe have rolled out mass immunization campaigns, which have demonstrated both efficacy and cost-efficiency. As water and sanitation improvements alone are insufficient in high-burden regions, governments are integrating vaccine programs into national immunization schedules. Moreover, the expanded support from organizations like Gavi, the Vaccine Alliance, is streamlining the financing and distribution of these vaccines, accelerating adoption in the regions most in need.

How Is Innovation Shaping The Efficacy And Reach Of Typhoid Fever Vaccines?

The evolution of typhoid vaccines from traditional live attenuated or inactivated types to conjugate vaccines has marked a pivotal advancement in terms of coverage, durability, and age-appropriate administration. Traditional vaccines like Ty21a and Vi polysaccharide had limitations in terms of age restriction (usually ineffective in children under 2) and shorter immunity. The new-generation Typhoid Conjugate Vaccines (TCVs), however, can be administered to children as young as 6 months and provide protection for up to 5 years or longer. This development has significant implications for pediatric immunization strategies in endemic regions. Furthermore, global clinical trials are exploring multi-pathogen conjugate vaccines that combine typhoid protection with other enteric diseases, such as paratyphoid and invasive non-typhoidal salmonella (iNTS). These innovations are particularly critical as antimicrobial resistance (AMR) continues to rise in Salmonella Typhi strains, rendering traditional antibiotic therapies less effective. As a result, preventive immunization is gaining traction as the most sustainable approach to typhoid control. Additionally, biotech firms are investing in thermostable formulations to mitigate cold-chain dependency, which remains a challenge in remote or under-resourced settings.

Can Strategic Policies And International Collaborations Bridge The Accessibility Gap?

As the global healthcare ecosystem becomes more interconnected, the role of policy frameworks and cross-border partnerships is proving vital to the proliferation of typhoid fever vaccines. The WHO's prequalification of TCVs has opened the doors for procurement by United Nations agencies, facilitating widespread implementation. Meanwhile, Gavi’s financial support for eligible countries has made vaccines affordable and accessible, particularly in sub-Saharan Africa and South Asia. These interventions are complemented by domestic policy reforms where ministries of health are incorporating typhoid vaccines into routine immunization schedules. Moreover, joint efforts among NGOs, health ministries, and international donors are focusing on strengthening surveillance systems, community awareness, and cold-chain infrastructure to ensure seamless distribution. Global initiatives such as the Coalition against Typhoid are also amplifying advocacy and fostering a data-driven approach to monitoring outbreaks and vaccine impact. Furthermore, the COVID-19 pandemic has highlighted the urgency of bolstering immunization systems, with governments increasingly recognizing the role of preventive vaccination as a tool for broader health resilience. Such a shift in perspective is driving new funding channels and accelerating regulatory approvals in historically underrepresented regions.

What’s Powering The Surge In Demand For Typhoid Vaccines Around The World?

The growth in the typhoid fever vaccines market is driven by several factors that are reshaping public health priorities and advancing immunization coverage globally. Firstly, the rise in multi-drug resistant (MDR) and extensively drug-resistant (XDR) typhoid strains has drastically limited treatment options, positioning vaccines as a primary line of defense. Secondly, a marked increase in urbanization without corresponding improvements in water and sanitation infrastructure in many LMICs has maintained high transmission rates, sustaining demand for preventive solutions. Thirdly, greater political commitment to combat enteric diseases, especially in Asia and Africa, has translated into comprehensive immunization campaigns and increased healthcare budgets. Additionally, improved diagnostic surveillance has enabled better identification of hotspots, allowing targeted vaccine deployment. From a technological standpoint, the development of pediatric-compatible, single-dose TCVs with extended efficacy has simplified immunization logistics and expanded age group eligibility. Moreover, rising health literacy and community engagement in vaccine initiatives have improved public receptivity, reducing vaccine hesitancy. Lastly, the growing presence of global and regional vaccine manufacturers has increased supply chain reliability, fostering a competitive environment that encourages innovation and price reduction-two key levers in expanding vaccine accessibility across diverse geographies.

SCOPE OF STUDY:

The report analyzes the Typhoid Fever Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine, Other Types); Administration Route (Oral, Injection); End-Use (Hospitals & Clinics, Specialty Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • Bavarian Nordic A/S
  • Bharat Biotech International Ltd.
  • Biological E. Limited
  • Bio-Med Pvt. Ltd.
  • Cadila Healthcare Ltd. (Zydus Lifesciences)
  • Chiron Behring Vaccines Pvt. Ltd.
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • Haffkine Bio-Pharmaceutical Corp. Ltd.
  • Incepta Vaccine Ltd.
  • Indian Immunologicals Ltd.
  • Merck & Co., Inc.
  • Panacea Biotec Ltd.
  • PaxVax, Inc.
  • Pfizer Inc.
  • Prokarium Ltd.
  • Sanofi Pasteur
  • Serum Institute of India Pvt. Ltd.
  • Shanta Biotechnics Ltd.
  • SK bioscience Co., Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Typhoid Fever Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Typhoid in Endemic Regions Spurs Vaccine Uptake
    • Government Immunization Programs Strengthen Business Case for Typhoid Vaccination
    • Public-Private Partnerships Drive Market Penetration in Low-Income Economies
    • Inclusion of Typhoid Conjugate Vaccines in National Immunization Schedules Propels Growth
    • Growing International Travel Generates Demand for Preventive Vaccines
    • Advancements in Conjugate Vaccine Technology Accelerate Market Expansion
    • Increasing Awareness Through Global Health Campaigns Spurs Demand
    • Cold Chain Infrastructure Improvements Sustain Growth in Remote Regions
    • Funding from Gavi and International Donors Strengthens Distribution Networks
    • Urban Sanitation Challenges Throw the Spotlight on Vaccination as a Preventive Strategy
    • Antibiotic Resistance Issues Drive Adoption of Preventive Vaccination
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Typhoid Fever Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Typhoid Fever Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Typhoid Fever Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Live Attenuated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Live Attenuated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Live Attenuated Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Capsular Polysaccharide Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Capsular Polysaccharide Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Capsular Polysaccharide Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Conjugate Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Conjugate Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Conjugate Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Injection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Specialty Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Specialty Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Specialty Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Typhoid Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Typhoid Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Typhoid Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Typhoid Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Typhoid Fever Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Typhoid Fever Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Typhoid Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Typhoid Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Typhoid Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Typhoid Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Typhoid Fever Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Typhoid Fever Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Typhoid Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Typhoid Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Typhoid Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Typhoid Fever Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Typhoid Fever Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Typhoid Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Typhoid Fever Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Typhoid Fever Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Typhoid Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Typhoid Fever Vaccines by Type - Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Typhoid Fever Vaccines by Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine and Other Types for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by Administration Route - Oral and Injection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Typhoid Fever Vaccines by Administration Route - Oral and Injection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Typhoid Fever Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral and Injection for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Typhoid Fever Vaccines by End-Use - Hospitals & Clinics, Specialty Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Typhoid Fever Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Specialty Centers and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION